| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Tetradecyl sulfate sodium does not have a defined biological target. Its function is physicochemical—as an anionic surfactant, it disrupts cell membranes and causes localized inflammation and fibrosis when injected into vascular lesions. In sclerotherapy, the compound is injected directly through the skin into a lesion, causing the vessel to close up. It is also used as a surfactant in various industrial applications.
|
|---|---|
| ln Vitro |
In vitro, tetradecyl sulfate sodium is used as a surfactant in various applications, including nickel plating baths, pickling, electrolytic cleaning, welding, and leather dyeing. It is used to study the time course of liquid drainage and foam coarsening. As a detergent-like sclerosant, it disrupts cell membranes. The compound is not tested for pharmacological activity in standard cell-based assays.
|
| ln Vivo |
In vivo, tetradecyl sulfate sodium is used as a sclerosing agent in sclerotherapy. It is injected directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. The compound causes localized inflammation and fibrosis, leading to the closure of the vascular lesion.
|
| Enzyme Assay |
In vitro assays for tetradecyl sulfate sodium focus on its surfactant properties rather than receptor binding. A standard protocol involves measuring surface tension using a tensiometer at varying concentrations of the compound in aqueous solution. Critical micelle concentration (CMC) is determined by conductivity or fluorescence methods. For sclerotherapy studies, the compound is tested in vascular tissue models to assess its effects on cell viability and vessel closure.
|
| Cell Assay |
In vitro cell culture experiments with tetradecyl sulfate sodium typically involve cytotoxicity studies to assess its effects as a sclerosant. A standard protocol involves culturing vascular endothelial cells in 96-well plates and treating them with varying concentrations of the compound (typically 0.1-10 mg/mL) for 24-48 hours. Cell viability is assessed using MTT or LDH release assays. The compound's effects on cell membrane integrity are measured.
|
| Animal Protocol |
In vivo animal studies with tetradecyl sulfate sodium are conducted to evaluate its efficacy as a sclerosing agent. A typical protocol involves injecting the compound into animal models of vascular malformations. The closure of the vascular lesion and the extent of fibrosis are assessed histologically. The compound is also used in studies of foam sclerotherapy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of tetradecyl sulfate sodium are not fully characterized. As a surfactant, it is locally injected and is not intended for systemic absorption. The compound is metabolized and cleared locally. No formal pharmacokinetic studies have been conducted, as it is used as a medical device or topical agent.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding the clinical use of sodium tetradecyl sulfate during lactation. While sodium tetradecyl sulfate is unlikely to have adverse effects on breastfed infants, international guidelines recommend suspending breastfeeding for 2 days after sclerotherapy. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Tetradecyl sulfate sodium may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from moisture and strong oxidizing agents. |
| References |
[1]. Tan KT, et al. Percutaneous sodium tetradecyl sulfate sclerotherapy for peripheral venous vascular malformations: a single-center experience. J Vasc Interv Radiol. 2007;18(3):343-351.
|
| Additional Infomation |
An anionic surfactant, widely used in industry due to its wetting properties, is used in medicine as a stimulant and sclerosing agent for hemorrhoids and varicose veins.
An anionic surfactant, widely used in industry due to its wetting properties, is used in medicine as a stimulant and sclerosing agent for hemorrhoids and varicose veins. Indications For the treatment of small, uncomplicated varicose veins of the lower extremities, characterized by simple dilation and normal valve function. Mechanism of Action Sodium tetradecyl sulfate is a potent endothelial cell toxin that effectively strips endothelial cells over considerable distances, even with brief exposure to low concentrations, exposing highly thrombotic endothelial cells in the process. Diluted sodium tetradecyl sulfate can also induce a hypercoagulable state, possibly through selective inhibition of protein C, and can also promote platelet aggregation. Pharmacodynamics Sodium tetradecyl sulfate is an anionic surfactant, a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy involves injecting a sclerosing agent directly through the skin into the lesion site. It is primarily used to treat low-flow-rate vascular malformations, particularly venous and lymphatic malformations. Intravenous injection can lead to intimal inflammation and thrombosis, which often obstructs the injected vein. Subsequent fibrosis can cause partial or complete occlusion of the vein, which may or may not be permanent. Tetradecyl sulfate sodium is an anionic surfactant used as a detergent-like sclerosant in sclerotherapy for the treatment of slow-flow vascular anomalies. It is also used as a surfactant in various industrial applications, including cosmetics, detergents, and pharmaceuticals. The compound has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C14H29NAO4S
|
|---|---|
| Molecular Weight |
316.43
|
| Exact Mass |
316.168
|
| CAS # |
1191-50-0
|
| PubChem CID |
23665770
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
199 °C
|
| LogP |
5.245
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
20
|
| Complexity |
275
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
|
| InChi Key |
UPUIQOIQVMNQAP-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C14H30O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17;/h2-14H2,1H3,(H,15,16,17);/q;+1/p-1
|
| Chemical Name |
sodium;tetradecyl sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (316.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1603 mL | 15.8013 mL | 31.6026 mL | |
| 5 mM | 0.6321 mL | 3.1603 mL | 6.3205 mL | |
| 10 mM | 0.3160 mL | 1.5801 mL | 3.1603 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
